In almost all of the comments on AMPE the excitement of ORP is almost all but ignored. With the new investment relationships (wished for in Part 1) one must consider the prospective Louxis IPO - and the corresponding prospect of a selling shareholder (AMPE selling part of its Louxis interest). Louxis and ORP can be huge, especially is coming out of the gate with a significant investment banker.
AMPE management is not dumb. They know the need for coverage from higher profile IBs. They know the need for cash in case Zertane fails to provide what they need. They recognize that them taking Ampion to market themselves would require significant dollars.
Now... following the news and its lukewarm reaction, we are seeing carefully placed purchases, acquiring at least a modest number of shares on the QT.
Wish I may and wish I might.... AMPE has a banker in sight!
I would expect that AMPE has already, or will soon, retain the services of a major investment bank. With Ampion results being so positive, they are in the driver's seat. They will probably shop it around to what should be a host of major drug companies that would love to get their hands on Ampion. With Synvisc & like prducts, and steroids, no longer being recommended by doctors, that leaves only Ampion. The market should be in the $Billions. Ampe is still an undiscovered company. As more institutions become aware of it, the stock price will trend higher - much higher.